Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05336812
Title Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Ohio State University Comprehensive Cancer Center
Indications

chronic lymphocytic leukemia/small lymphocytic lymphoma

Therapies

Acalabrutinib + Venetoclax

Acalabrutinib + Obinutuzumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.